Aurora, ILLINOIS18 Active Studies

Erectile Dysfunction Clinical Trials in Aurora, ILLINOIS

Find 18 actively recruiting erectile dysfunction clinical trials in Aurora, ILLINOIS. Connect with local research sites and explore new treatment options.

18
Active Trials
15
Sponsors
6,536
Enrolling

Recruiting Erectile Dysfunction Studies in Aurora

RecruitingAurora, ILLINOISNCT04626635

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

This study is researching an investigational drug called REGN7075 by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors ...

933 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingAurora, ILLINOISNCT04262466

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a fi...

727 participants
Immunocore Ltd
View Study Details
RecruitingAurora, ILLINOISNCT05768139

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with...

720 participants
Eli Lilly and Company
View Study Details
RecruitingAurora, ILLINOISNCT06112314

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanc...

680 participants
Immunocore Ltd
View Study Details
RecruitingAurora, ILLINOISNCT03093116

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotre...

500 participants
Turning Point Therapeutics, Inc.
View Study Details
RecruitingAurora, ILLINOISNCT06380751

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positiv...

500 participants
AstraZeneca
View Study Details
RecruitingAurora, ILLINOISNCT05267821

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in chil...

500 participants
Nationwide Children's Hospital
View Study Details
RecruitingAurora, ILLINOISNCT06697197

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors....

413 participants
Bristol-Myers Squibb
View Study Details
RecruitingAurora, ILLINOISNCT02332668

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cance...

370 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingAurora, ILLINOISNCT05398484

Psilocybin Therapy in Advanced Cancer

The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existent...

300 participants
NYU Langone Health
View Study Details
RecruitingAurora, ILLINOISNCT06072482

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)....

300 participants
Amgen
View Study Details
RecruitingAurora, ILLINOISNCT05902988

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers....

120 participants
Volastra Therapeutics, Inc.
View Study Details
RecruitingAurora, ILLINOISNCT04068194

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and ...

103 participants
National Cancer Institute (NCI)
View Study Details
RecruitingAurora, ILLINOISNCT05327010

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment a...

88 participants
National Cancer Institute (NCI)
View Study Details
RecruitingAurora, ILLINOISNCT05135975

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, a...

86 participants
Nationwide Children's Hospital
View Study Details
RecruitingAurora, ILLINOISNCT04652882

Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD....

70 participants
Vanda Pharmaceuticals
View Study Details
RecruitingAurora, ILLINOISNCT06840483

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with NECTIN4-amplified recurrent, unresectable, or metastatic breas...

66 participants
BicycleTx Limited
View Study Details
RecruitingAurora, ILLINOISNCT05785819

A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspecte...

60 participants
Veralox Therapeutics
View Study Details

About Erectile Dysfunction Clinical Trials in Aurora

Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.

There are currently 18 erectile dysfunction clinical trials recruiting participants in Aurora, ILLINOIS. These studies are seeking a combined 6,536 participants. Research is being sponsored by Regeneron Pharmaceuticals, Immunocore Ltd, Eli Lilly and Company and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Erectile Dysfunction Clinical Trials in Aurora — FAQ

Are there erectile dysfunction clinical trials in Aurora?

Yes, there are 18 erectile dysfunction clinical trials currently recruiting in Aurora, ILLINOIS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Aurora?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you about next steps.

Are clinical trials in Aurora free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Aurora studies also compensate for your time and travel.

What erectile dysfunction treatments are being tested?

The 18 active trials in Aurora are testing new therapies including novel drugs, biologics, and treatment approaches for erectile dysfunction.

Data updated March 2, 2026 from ClinicalTrials.gov